In the Affirmative, Vol.5, No.7 (Mid-July/ Mid-September 1998)

Mick Martin

The AIDS Project

Follow this and additional works at: http://digitalcommons.usm.maine.edu/affirmative

Part of the American Studies Commons, Lesbian, Gay, Bisexual, and Transgender Studies Commons, and the Public Health Commons

Recommended Citation

Prevention Is Key
Says AIDS Conference

12th World AIDS Conference is held in Geneva, Switzerland

from The New York Times

The 12th World AIDS Conference ended on Friday, July 3, 1998 in a somber mood. A series of reports about problems with anti-AIDS drugs and setbacks in vaccine trials left many participants thinking that their best hope against the epidemic is prevention. But many of them said this last hope was not being pursued as aggressively as it should be.

The mood was a sharp contrast to the euphoria at the last AIDS meeting in Vancouver, British Columbia, two years ago. There, scientists reported that combinations of new drugs called protease inhibitors had allowed many people infected with HIV, the AIDS virus, to leave their deathbeds, even to return to work. But this year, the talk was of problems. Vaccine researchers gave the disheartening news that a promising candidate vaccine, tested in monkeys, caused the disease rather than prevented it. Doctors told of patients who failed in spite of the new drugs, or who developed side effects while taking them. And even when the drugs offered hope, still other speakers said, it is hope beyond the reach of the vast majority of the 34 million people now infected with the AIDS virus. Those patients cannot afford the treatment. It can cost about $15,000 to provide the drugs to one person a year, a sum greater than the entire health budgets of many a Third World village.

As Dr. Hoosen Coovadia, of Durban, South Africa, explained it, AIDS affects 40 percent of the children he treats in a large black hospital there. Yet, Coovadia, who is chairman of the next World AIDS Conference in 2000 in Durban, said that he had never used any anti-HIV drugs. His hospital cannot afford them, he said.

Reports like these lead inexorably to the conclusion that the best hope for easing the epidemic is still prevention, speakers said. Yet "over 100 times more money is being spent on therapeutics now than on the development of prevention technologies," said Dr. Catherine Hankins, an epidemiologist at Montreal General Hospital in Canada. Among them are chemicals that could be inserted into the vagina before sexual intercourse to kill HIV. Hankins left the meeting saying she did not feel "terribly optimistic".

Sex education, needle exchange programs, condom distribution, among other prevention methods, could save millions of people from AIDS, speaker after speaker told those gathered at the meeting. At the same time, though, many of the 13,775 participants from 177 countries concluded that people and their government leaders were not paying enough attention to those relatively simple steps, and that industry was doing too little to develop more effective prevention methods.

Speakers urged that health workers combine prevention as they had drugs and adopt a community-based approach to promote them. They called for more programs to treat sexually transmitted diseases because those diseases can increase the risk of spreading HIV, in part by creating open sores.
It is an interesting time to be HIV infected, from both a global and a local perspective. The 12th World AIDS Conference just ended about two weeks ago and the news out of Geneva was voluminous and somber. In a nutshell, the conclusion of the conference is that things are not as optimistic as they seemed two years ago at the last World AIDS Conference in Vancouver. Of course, there was a fair amount of talk about a “cure” then, but time spent following patients taking the protease inhibitors has dampened spirits a bit.

Proteases were the miracle drugs that were going to turn HIV/AIDS into a manageable, chronic disease, so they said two years ago. It hasn’t turned out that way. There are some pretty miraculous cases of people taking proteases who have had wonderful changes in their health. The proteases and other drugs are working wonders for many. Still, many cannot tolerate the drugs, get no benefit from the drugs, or have become resistant to the drugs. And on a global basis, the drugs are simply not affordable to the vast majority of infected people.

And there are some disconcerting side effects showing up in some people who have been on proteases for a while now. News that heart problems, diabetes, and disfiguring fatty lumps are showing up poses the dilemma, do the drugs’ benefits outweigh their dangers? -Scientists say yes, but very cautiously.

And a couple of cases of a new drug resistant strain of the virus is causing concern. Just as was seen after AZT had been in use for awhile, where people were being infected with a strain of the virus already resistant to AZT because the carrier was resistant to AZT, so too are there a couple of cases of people getting infected with a strain resistant to the proteases and other widely used drugs. What this means for those newly infected with this strain is that they won’t receive any benefit from taking the drugs they’ve never even tried.

Still, all the news was not negative. Lots of research continues on drugs, treatments, and vaccines that may be the breakthrough we’re all hoping for. And now that almost everyone agrees in the importance of a vaccine (though not which kind of vaccine) in curbing the worldwide epidemic, greater efforts in that area will result. And now that it is understood that the dosing schedules are often too complicated and cumbersome for patients, efforts are in the works to make staying drug compliant easier.

The big conclusion, though, is not really new at all. That conclusion is the urgent importance of prevention education. It may sound simple, but keeping people from getting the virus is still the best hope for the future. And with reports in this country that gay and bisexual male youth are not as diligent in practicing safer sex as older gay and bisexual men, prevention education is needed more than ever. Some reports have pointed out the success of small-group prevention education programs, showing that prevention efforts can and do work. The success of many needle exchange programs was also noted as an area of prevention work that needed more attention. The conference said that more money and effort is needed worldwide for prevention education, particularly given the less-than-hoped-for results with drug treatments.

Advances in the understanding of the virus continue and I’ve tried to include a lot of articles in this newsletter with information from before and during the conference which I think are of interest.

Locally, the Reconstruction forums have started. They are examining what the future holds for people with HIV who are doing well, or better than they were doing before. And as an added bonus, the forums will help local AIDS service organizations examine ways they may need to change to support those clients. The forums continue through the first week of August and I encourage anyone interested in the future of HIV in our area to attend. If nothing else, it is a great learning experience.

It is six years ago this month that Roy Keller died of AIDS. Apart from being a very likable guy, he was the “idea man” behind getting this newsletter from The AIDS Project off the ground. He talked about the need for a local newsletter for clients for long enough, that it finally happened. Our first issue came out in December 1993, six months after his death. In hindsight, it seems like such an obvious idea to have this newsletter, but the obvious is often the hardest to achieve. Perhaps, that is why Roy and his idea deserve to be remembered from time to time.
AIDS Medication May Cause Buffalo Humps

Some HIV-infected people have been developing abnormal fatty deposits, called buffalo humps and protease paunches, which may stem from the use of protease inhibitors. While the patients lose fat and muscle from the hips and below, as well as in their arms and faces, they add visceral fat under the abdominal muscles and behind the neck. The FDA is worried that the drugs are also causing an increase in risk for heart disease. Aside from the deforming fat deposits, the drugs may cause an increase in cholesterol. Despite the concerns, most agree that the benefits of the treatment outweigh the adverse effects. One of the makers of protease inhibitors, Merck and Co., asserts that there is no proof that the medication is the causative factor, noting that the fatty deposits could be a previously unseen effect of the virus or a result of the combination of other drugs. However, the FDA contends that the four protease inhibitors now on the market are the primary causative suspects, and it is currently investigating 64 case reports. One Australian study of 75 HIV-infected subjects found that the buffalo humps are a common complication of the treatment. Currently, researchers estimate that anywhere from 5 percent to 64 percent of HIV-infected patients may have the disfigurements to some degree.

Gonorrhea Most Notifiable Infectious Disease Among U.S. Women

Gonorrhea is the most commonly identifiable infectious disease among women 55 years and younger in almost all racial groups, according to the CDC. Analyzed data on 48 infectious diseases among women aged 13 to 55 that were reported to local or state health departments between 1992 and 1994 found that the 10 most common diseases, in descending order of frequency, were gonorrhea, primary/secondary syphilis, AIDS, salmonellosis, tuberculosis, hepatitis A, hepatitis B, shigellosis, Lyme disease, and hepatitis C (non-A, non-B).

Swaziland: AIDS Solutions

Swaziland's Aids minister has recommended a number of methods to help control the spread of HIV in that nation, including the branding of needle deposits, the spread of HIV, and do not increase drug use. The CDC has found that all of the rapid-progressors in the group and half of the late-progressors had viral variations that allowed HIV to enter host cells through co-receptors other than CCR5. The viruses in long-term non-progressors did not show this variation.

New Drug Mix Would Simplify HIV Therapy

Researchers from the CDC report that progression rates in people with HIV are linked to co-receptor types. In some people, HIV enters host cells only through the CCR5 receptor, while others carry viruses that can enter the host cell through a number of receptors. A CDC biologist examined virus samples taken from HIV-positive men at various stages of disease progression and found that all of the rapid-progressors in the group and half of the late-progressors had viral variations that allowed HIV to enter host cells through co-receptors other than CCR5. The viruses in long-term non-progressors did not show this variation.

Continued Risk Behavior Among Young Gay Men in the U.S. Points to Need for Sustained Prevention and Suggests a Focus on Social Influences

A study by the CDC shows that young gay men in the United States are more likely to practice unsafe sex and contract HIV as compared to their older counterparts. The study investigated sexual habits among HIV-negative gay and bisexual men in Denver, Chicago, and San Francisco. Almost two-thirds of the gay men reported that they had engaged in unprotected anal sex in the previous 18 months and 56 percent of gay men aged under 25 years said that they had engaged in unprotected receptive anal intercourse in the same time frame. Comparatively, 46 percent of older gay men reported that they had engaged in the same risky activity in the prior 18 months. The study found that the increased risk habits are associated with perceived peer norms concerning unprotected anal sex. Additionally, young gay men who socialize and meet partners in bars were more likely to have unprotected sex. The researchers suggested that prevention efforts focus on changing peer norms and reaching young men in bar settings.
**HIV news**

Where the Female Condom Is No Joke

The female condom, manufactured by Female Health in Chicago, had a poor debut in the United States when it was introduced in 1994, but found much more support in the developing world. The Joint United Nations Program (UNAIDS) has been heavily advocating the female condom as a method of preventing pregnancy and sexually transmitted diseases. In addition, thanks to a volume discount negotiated by UNAIDS the cost of the female condom went from about $2.50 to under $1, and African nations have purchased millions of the condoms in an effort to help control the spread of HIV.

South Africa has bought 1.5 million female condoms, while Uganda bought 1.2 million and Zambia and Zimbabwe also made significant purchases. According to the president of Female Health, one-fifth of Botswana's sexually active population has AIDS and the average lifespan has dropped by about 20 years. More women than men are infected with HIV in Uganda, with the most infected group aged 20 to 30 years old. While the female condom does not seem to be as popular as the male condom, studies with female sex workers in Thailand found the condom to be among women who had both options available to them, there was a 34 percent decrease in the rate of sexually transmitted diseases and a 25 percent decrease in the number of unprotected sex acts, compared to women who only had male condoms available to them. The female condom, a prelubricated, disposable polyurethane sheath that is inserted into the vaginal canal prior to intercourse, allows women to control contraception without male consent, providing another option for women with limited contraception choices.

PCP Mutations May Explain Prophylaxis Failures

Research suggests that two amino acid mutations in Pneumocystis carinii (PCP) may be the cause of prophylaxis failure in some patients with AIDS. Doctors at the University of Michigan Medical Center in Ann Arbor analyzed P. carinii specimens from 27 patients, including 20 who had AIDS. They detected mutations at two amino acid positions, particularly in patients who received prophylaxis with sulfa/sulfone. The mutations appeared to be correlated with substrate and sulfa binding and may be behind prophylaxis failure in AIDS patients.

**Toward HIV Eradication or Remission: The Tasks Ahead**

Dr. David D. Ho of the Aaron Diamond AIDS Research Center at Rockefeller University in New York City, describes the current state and future goals of HIV/AIDS treatment and eradication. Despite the substantial declines in AIDS incidence and mortality over the past two years, latent reservoirs of HIV cells remain in the host body during combination therapy. Ho calculates that given the estimated decay rate of infected memory CD4 lymphocytes, combination therapy would have to be maintained for a minimum of five to seven years in order to eliminate the latent reservoirs of HIV infection. Regimens lasting 10 or more years would be required for larger reservoir sizes. Given the toxicity, cost, and complexity of combination treatment, a regimen lasting this long is "unacceptable," according to Ho. Increasing the decay rate while maintaining antiretroviral therapy may be a viable strategy. Ho notes that to achieve this, it may be required to activate the latent reservoirs. Introducing antigens or cytokines may result in the activation of sufficient resting T cells. Many of the activators, though, are associated with clinical toxicity. Another strategy may be to induce remission. This could be achieved by increasing the threshold level at which the immune system can control the HIV infection through the use of a vaccine or through the intermittent disruption of antiretroviral therapy in order to increase specific immune responses.

**Live HIV Vaccine's Safety Doubt**

Researchers at the 12th AIDS Conference in Geneva presented findings of experiments in monkeys that suggest a live attenuated AIDS vaccine may not be possible because it provides limited protection and can lead to illness. In the monkey experiments, the researchers said the experimental vaccine prevented simian immunodeficiency virus (SIV) infection, the monkey equivalent of HIV, in about half of the 15 adults vaccinated and did not provide full protection to any of the mothers' nine offspring. The findings are similar to a study of eight Australians infected with an HIV strain with the same missing gene, nef, which is similar to the vaccine; but several of the patients with the missing gene had a slight decrease in CD4 levels, which suggests "something is happening," according to Jennifer Learmont, a nurse with the Australian Red Cross involved in the study. Despite the concerns, the International Association of Physicians in AIDS Care said a human study involving a vaccine was the only way to determine the true efficacy of a live attenuated vaccine.

Anemia Increases Death Risk in AIDS Patients

Several studies presented at the 12th World AIDS Conference in Geneva, indicate that untreated anemia can increase the risk of mortality in HIV and AIDS patients. Researchers at Johns Hopkins University found that among 1,234 HIV-positive patients treated, anemia resulted in increased death rates, even when coupled with improvements in viral load, CD4 cell count, patient age, and opportunistic infections. Treatment of HIV with AZT has been associated with increased incidence of anemia, which can be treated with blood transfusions or with recombinant human erythropoetin, a drug which boosts red-cells. Johns Hopkins' Richard Moore also cited recent data from the Centers for Disease Control and Prevention which indicated that on average, survival among people who had recovered from anemia was similar to that of people who had never had the disease.

AIDS Drug Said to Combat Hepatitis B

A study published in the *New England Journal of Medicine* indicates that the AIDS drug lamivudine, also called Epivir or 3TC, may slow liver damage associated with hepatitis B virus infection. Researchers from the University of Hong Kong examined the effects of one year of treatment in 358 patients in China and found that inflammation signs decreased by just over 50 percent of those receiving the medications, while only 25 percent of those receiving placebo showed a decrease in inflammation. The drug, manufactured by Glaxo Wellcome, inhibits reverse transcriptase, an enzyme used by both HIV and the hepatitis B virus. Alpha interferon is the only medication currently approved for the treatment of hepatitis B, but scientists noted that 3TC is easier to take and may work better, although comparison studies have not been done.

First Oral Herpes Drug for HIV Patients Approved

The Food and Drug Administration has approved the use of Famvir for the treatment of recurrent herpetic lesions in HIV-infected individuals. Many people infected with HIV are also infected with some form of the herpes simplex virus. Research indicates that genital herpes may be a significant factor in HIV transmission. Famvir, manufactured by SmithKline Beecham, is the first oral drug approved for herpes treatment in HIV-positive patients. The drug has been cleared for the treatment of recurrent genital herpes and shingles in HIV-negative people.

---

**Sources for some of the material in this newsletter:**

HIV news

AIDS Groups Stunned by New York’s Passage of HIV Tracking Bill

News that New York State had approved an HIV tracking bill surprised AIDS activists, who had not expected the legislation to be passed in this session. The measure mandates the name reporting of HIV-positive individuals to the state and requires that government workers contact the sexual partners of those infected. However, some advocates say the legislation will make some people even more reluctant to be tested. According to Jeffrey L. Reynolds, of the Long Island Association for AIDS Care, "We have enacted a law that will drive people from testing because of the fear of being identified in their community and the fear of having the Health Department at your front door." Under the bill, individuals who refuse to name their sexual partners will not be penalized and some anonymous testing sites will be maintained.

Bill to Criminalize Knowingly Spreading of HIV Is Vetoed

Alaska Governor Tony Knowles vetoed a bill that would have made it a felony to knowingly spread HIV. The measure, approved last month by the state legislature, would have made it a crime to sell tainted blood or to have sex with someone who is unaware of their partner’s infected status. In explaining his decision, Knowles said the bill "would for the first time criminalize a disease in Alaska," noting that the state’s current laws against reckless endangerment and several forms of assault already protect its citizens.

Drug May Offer Hope for AIDS

A top AIDS researcher said Thursday that certain monoclonal antibodies, such as Ortho Biotech’s OKT3, may be effective in flushing the body of HIV that often remains in a patient’s body after treatment with drug cocktails that have eliminated all signs of infection in some patients. Even though the infection is not evident, experts believe HIV can hide in resting immune cells for years. In a commentary in the journal Science, Dr. David Ho, of the Aaron Diamond AIDS Research Center in New York, said that activators such as bacterial superantigens or a certain class of monoclonal antibodies may be able to stimulate the immune cells where HIV is hiding and completely flush HIV from the body.

House Calls Help Curb TB

In Sacramento County, Calif., health officials are making house calls to patients with tuberculosis to ensure that they take their medicine. Directly observed treatment, short course (DOTS), has proven to be the best way to control TB and drug resistance, which can develop when treatment regimens are not completed. A recent study in the Journal of the American Medical Association reported that over 90 percent of patients with tuberculosis will complete treatment through DOTS. California recommends, but does not require, counties to deliver and observe patients taking their drugs; currently, about 30 percent of patients statewide do receive the therapy. Nearly 50 percent of the 115 TB patients in Sacramento County are receiving DOTS, which is credited for the success in treating virtually all of the county’s cases.

FDA Approves New Treatment for Tuberculosis

The FDA has approved the marketing of rifapentine for the treatment of TB, marking the first new drug for the condition in more than a decade. Doctors and researchers are applauding the new drug, which remains in the blood stream for longer periods, allowing the number of weekly doses to be reduced by half. The new drug should make it easier for patients to complete treatment and help prevent the development of resistant strains. In clinical trials, one group of patients was administered rifapentine twice weekly for two months and then once a week for four months, while a second group was given the standard therapy, rifampin, twice a week in the final four months; about 82 to 88 percent of the patients in both groups were cured. In the early months of therapy, patients in both groups were given three other tuberculosis drugs to help lower the possibility of drug resistance.

Antiretroviral Drug Resistance Testing in Adults With HIV Infection

A panel of scientists convened by the International AIDS Society/USA Panel has concluded that plasma HIV RNA levels and CD4 cell counts are the main values that should be employed to determine when to start antiretroviral therapy and subsequent changes in therapy. In addition to drug resistance as a cause of treatment failure, the team said that adherence, drug potency, and pharmacokinetic issues should also be reviewed.

After reviewing data from published reports and material presented at research conferences, the team said genotypic and phenotypic testing for HIV resistance to antiretroviral drugs may also be beneficial in managing individual cases. In particular, emerging evidence indicates that in drug-experienced patients, genotypic and phenotypic signs of resistance to the drug in vitro implies poor virologic response in vivo. In these cases, resistance testing will be beneficial in identifying drugs that will not be useful in some regimens. However, the lack of phenotypic or genotypic evidence does not necessarily mean that patients will respond favorably. Furthermore, the researchers said assays that are currently being developed need to be validated and standardized, and developers need to determine a clear definition of the assays’ clinical roles. Researchers should also track the prevalence of drug resistance in populations where the resistance is most common, especially among antiretroviral drug-naive pregnant women or individuals with primary HIV infection. A pattern may help physicians choose initial antiretroviral therapies for such groups.

Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance

The widespread use of antiretroviral therapies and the rising incidence of strains of HIV that are resistant to those therapies have opened the door to a number of important concerns, ranging from the relationship between drug resistance and treatment failure to public health ramifications. Among the issues are: the frequency with which resistant strains are transmitted through sexual contact, intravenously, or from mother to child; the ability of drug-resistant strains to be transmitted; and the usefulness of antiretroviral therapy in reducing viral levels in blood and genital fluids. The importance of patients sticking to drug regimens is also important. As well as the relationship of adherence to drug regimens to sustained reduction in viral load to minimize the possibility of transmitting a drug-resistant strains through blood or genital secretions. If the issue of preventing the development of drug-resistant strains and the spread of such strains are not addressed, researchers expect the possibility that drug-resistant strains can replicate will help to maintain the epidemic and reduce the beneficial effects of antiviral therapy.

Spectrum of AIDS-Associated Malignant Disorders

New data from the AIDS-Cancer Match Study Group suggests that AIDS results in a substantially greater risk of Hodgkin’s disease, multiple myeloma, brain cancer, and seminoma. The researchers compared the cancers of AIDS patients to those in the general population by matching population-oriented AIDS and cancer registries in the United States and Puerto Rico. Among the more than 98,000 AIDS cases studied, there were 7,028 cases of Kaposi’s sarcoma, 1,793 of non-Hodgkin lymphoma (NHL), and 712 other cases of histologically defined cancer. The incidence rates among AIDS patients were raised 310-fold for KS, 113-fold for NHL, and 1.9-fold for all other cancers. The authors concluded that “AIDS is associated with neoplasms already thought to be linked to common viruses,” although most of the common malignant disorders are not specifically related to immunodeficiency.

The AIDS Project welcomes two new staff members.

Demetra Giatas has been hired as TAP’s new Development Director. And John Cronin joins the Prevention Education department for the summer.
HIV news

Where the Female Condom Is No Joke

The female condom, manufactured by Female Health in Chicago, had a poor debut in the United States when it was introduced in 1984, but found much more support in the developing world. The Joint United Nations Program on HIV/AIDS (UNAIDS) has been heavily advocating the female condom as a method of preventing pregnancy and sexually transmitted diseases. In addition, thanks to a volume discount negotiated by UNAIDS the cost of the female condom went from about $2.50 to under $1, and African nations have purchased millions of the condoms in an effort to help control the spread of HIV. South Africa has bought 1.5 million female condoms, while Uganda bought 1.2 million and Zambia and Zimbabwe also made significant purchases. According to the president of Female Health, one-fifth of Botswana's sexually active population has AIDS and the average lifespan has dropped by about 20 years. More women than men are infected with HIV in Uganda, with the most infected group aged 20 to 30 years old. While the female condom does not seem to be as popular as the male condom, studies with female sex workers in Thailand found that among women who had both options available to them, there was a 34 percent decrease in the rate of sexually transmitted diseases and a 25 percent decrease in the number of unprotected sex acts, compared to women who only had male condoms available to them. The female condom, a prelubricated, disposable polyurethane sheath that is inserted into the vaginal canal prior to intercourse, allows women to control contraception without male consent, providing another option for women with limited contraception choices.

PCP Mutations May Explain Prophylaxis Failures

Research suggests that two amino acid mutations in Pneumocystis carinii (PCP) may be the cause of prophylaxis failure in some patients with AIDS. Doctors at the University of Michigan Medical Center in Ann Arbor analyzed P. Carinii specimens from 27 patients, including 20 who had AIDS. They detected mutations at two amino acid positions, particularly in patients who received prophylaxis with sulfa/sulfone. The mutations appeared to be correlated with substrate and sulfone binding and may be behind prophylaxis failure in AIDS patients.

Toward HIV Eradication or Remission: The Tasks Ahead

Dr. David D. Ho of the Aaron Diamond AIDS Research Center at Rockefeller University in New York City, describes the current state and future goals of HIV/AIDS treatment and eradication. Despite the substantial declines in AIDS incidence and mortality over the past two years, latent reservoirs of HIV cells remain in the host body during combination therapy. Ho calculates that given the estimated decay rate of infected memory CD4 lymphocytes, combination therapy would have to be maintained for a minimum of five to seven years in order to eliminate the latent reservoirs of HIV infection. Regimens lasting 10 or more years would be required for larger reservoir sizes. Given the toxicity, cost, and complexity of combination treatment, a regimen lasting this long is "unacceptable," according to Ho. Increasing the decay rate while maintaining antiretroviral therapy may be a viable strategy. Ho notes that to achieve this, it may be required to activate the latent reservoirs. Introducing antigens or cytokines may result in the activation of sufficient resting T cells. Many of the activators, though, are associated with clinical toxicity. Another strategy may be to induce remission. This could be achieved by increasing the threshold level at which the immune system can control the HIV infection through the use of a vaccine or through the intermittent disruption of antiretroviral therapy in order to increase specific immune responses.

Live HIV Vaccine's Safety Doubt

Researchers at the 12th AIDS Conference in Geneva presented findings of experiments in monkeys that suggest a live attenuated AIDS vaccine may not be possible because it provides limited protection and can lead to illness. In the monkey experiments, the researchers said the experimental vaccine prevented simian immunodeficiency virus (SIV) infection, the monkey equivalent of HIV, in about half of the 15 adults vaccinated and did not provide full protection to any of the mothers' nine offspring. The findings are similar to a study of eight Australians infected with an HIV strain with the same missing gene, nef, which is similar to the vaccine; but several of the patients with the missing gene had a slight decrease in CD4 levels, which suggests "something is happening," according to Jennifer Learmont, a nurse with the Australian Red Cross involved in the study. Despite the concerns, the International Association of Physicians in AIDS Care said a human study involving a vaccine was the only way to determine the true efficacy of a live attenuated vaccine.

Anemia Increases Death Risk in AIDS Patients

Several studies presented at the 12th World AIDS Conference in Geneva, indicate that untreated anemia can increase the risk of mortality in HIV and AIDS patients. Researchers at Johns Hopkins University found that among 2,343 HIV-positive patients treated, anemia resulted in increased death rates, even when coupled with improvements in viral load, CD4 cell count, patient age, and opportunistic infections. Treatment of HIV with AZT has been associated with increased incidence of anemia, which can be treated with blood transfusions or with recombinant human erythropoetin, a drug which boosts red-cells. Johns Hopkins' Richard Moore also cited recent data from the Centers for Disease Control and Prevention which indicated that on average, survival among people who had recovered from anemia was similar to that of people who had never had the disease.

AIDS Drug Said to Combat Hepatitis B

A study published in the New England Journal of Medicine indicates that the AIDS drug lamivudine, also called Epivir or 3TC, may slow liver damage associated with hepatitis B virus infection. Researchers from the University of Hong Kong examined the effects of one year of treatment in 358 patients in China and found that inflammation signs decreased in just over 50 percent of those receiving the medications, while only 25 percent of those receiving placebo showed a decrease in inflammation. The drug, manufactured by Glaxo Wellcome, inhibits reverse transcriptase, an enzyme used by both HIV and the hepatitis B virus. Alpha interferon is the only medication currently approved for the treatment of hepatitis B, but scientists noted that 3TC is easier to take and may work better, although comparison studies have not been done.

First Oral Herpes Drug for HIV Patients Approved

The Food and Drug Administration has approved the use of Famvir for the treatment of recurrent herpes in HIV-infected individuals. Many people infected with HIV are also infected with some form of the herpes simplex virus. Research indicates that genital herpes may be a significant factor in HIV transmission. Famvir, manufactured by SmithKline Beecham, is the first oral drug approved for herpes treatment in HIV-positive patients. The drug has also been cleared for the treatment of recurrent genital herpes and shingles in HIV-negative people.

Sources for some of the material in this newsletter:
crunching the numbers: an AIDS update

AIDS in the U.S.* (from the beginning to 12/97)
641,086 cases
390,692 deaths; a death rate of 61%
*does not include people diagnosed as HIV-positive only.

AIDS in Maine** (from the beginning to 6/98)
827 cases
439 deaths; a death rate of 53%
**includes only individuals residing in Maine at the time of their HIV diagnosis; and does not include people diagnosed as HIV-positive only.

Did you know? Almost half of all AIDS diagnoses in Maine and almost half of all deaths from AIDS in Maine have happened in the last five years.

In Maine in the first six months of 1998:
10 Men have been diagnosed with AIDS
4 Women have been diagnosed with AIDS
1 Child has been diagnosed with AIDS

a world of difference

It is estimated that HIV infects 34 million people worldwide

In the U.S., the fastest growing populations with HIV are women and minorities.
5% of the HIV population in the U.S. is in prisons.
In the U.S., while blacks make up only 13% of its population, they make up 57% of new HIV infections.
19% of the 1.3 million infected in Latin America are female.

90% of all cases in Europe are in Western Europe.
Cases in Eastern Europe went from 30,000 in 1994 to 190,000 in 1996.
Romania has two-thirds of all cases in Eastern Europe.

Thailand estimates 1 million of its population is HIV-positive.
In Vietnam, HIV infection has doubled since 1996.

Africa, which has 10% of the world's population, has 70% of all cases of AIDS.
In some areas of Africa, 1 in 4 persons is infected with HIV.
In Africa, people between the ages of 15 and 40 are most affected.
In Africa, it is estimated that 90% of all infected people are unaware of their HIV status.

Worldwide in 1997: 5.6 million people became infected with HIV.
Worldwide in 1997: 2.3 million people died from AIDS.
Worldwide since reporting began: 11.7 million people have died from AIDS.
TAP support groups for people infected and affected by HIV and AIDS

**tuesdays**

**Time:** 10:30 a.m. to noon

**Group:** HIV Infected/Affected Drop-In Support Group
A meeting for people living with and affected by the virus.
Location: Portland, TAP, The Meeting Place, Suite 632.
Contact Randy May at TAP at 774-6877 for more information.

**Time:** 1:00 p.m. to 2:30 p.m.

**Dates:** 2nd and 4th Tuesdays
**Group:** Women's Drop-In Support Group
A bi-weekly meeting of women living with HIV/AIDS or directly affected by the disease (through spouse/partner, parent, or child). Sponsored by TAP and The AIDS Consultation Service (ACS) at Maine Medical Center.
Location: Portland, ACS, 52 Gilman Street.
Contact Janine Collins at TAP at 774-6877 or Cindy Luce at ACS at 871-2991 for more information.

**Time:** 1:30 p.m. to 3:00 p.m.

**Group:** People Living with HIV
An ongoing drop-in support group for anyone with HIV/AIDS.
Location: Auburn, TAP, One Auburn Center.
Contact Diana Carrigan at TAP at 783-4301 for more info.

**thursdays**

**Time:** 10:00 a.m. to 11:30 a.m.

**Group:** HIV Infected/Affected Drop-in Group
A TAP-sponsored meeting for people living with and affected by HIV/AIDS in southern Maine.
Location: Sanford, Unitarian Church, located at the corner of Main St. (Rte. 109) and Lebanon St. (Rte. 202).
Contact Betty Payson at TAP at 985-8199 for more info.

**Time:** 12 noon

**Group:** Open Lunch for TAP Clients/Staff
An informal luncheon gathering of TAP staff and clients.
Location: Portland, TAP, Conference Room.
Contact Randy May at TAP at 774-6877 for more information.

**Time:** 5:30 p.m. to 7:00 p.m.

**Group:** People Living with HIV/AIDS
A drop-in support group for anyone with HIV/AIDS.
Location: Portland, TAP, The Meeting Place, Suite 632.
Contact Randy May at TAP at 774-6877 for more information.

**client services**

**medical assistance funds**

An important reminder to clients:

There are funds available to TAP clients with financial need for the following items:
Route Dental Care, Routine Eye Care and Eyeglasses, Vitamin Supplements, Non-Prescription Skin Care Products, and Non-Medicaid Medication Co-pays.
There is a dollar limit to how much a client can receive in any fiscal year. Contact your case manager for assistance by calling TAP.

**free lunch**

Enjoy a free lunch at The AIDS Project every Thursday at noon. Join other clients and TAP staff for a great meal, good conversation, and very good company. Drop by on Thursdays at noon!

**immediate seating**

For free tickets to area events as they become available, sign up with Robert for "Immediate Seating." Robert can be contacted directly on Friday afternoons by calling TAP at 774-6877, or you can call other times during the week and leave a message for him with the reception person.

**IV league**

Meetings of the I.V. League support group are held on Wednesdays.
The morning group meets from 8:00 to 9:30 at Discovery House in Portland.
The evening group meets from 6:30 to 8:00 at the Community Resource Center in Portland.
For more info, call the City of Portland Public Health Division at 756-8257.

**the meeting place**

This room is used by TAP in Portland for support groups, counseling and testing, and some client/case manager meetings. Located in Suite 632, it provides more privacy for people served by TAP. Enter from the High Street side of the building.

**for your information**

**HIV websites**

Check out these websites:
www.hivpositive.com
www.thebody.com
www.projectf.org
for info on HIV and AIDS.

**AIDS hotlines**

Questions about HIV/AIDS?
Call toll free
National AIDS Hotline: 1-800-342-2437
Maine AIDSline: 1-800-851-2437
Maine Teen Hotline: 1-800-851-2437
(on Wednesdays from 6-9pm)

**the AIDS project on-line**

Visit our web address at: “www.aidsproject.org”
To e-mail The AIDS Project, send your message along to “tapi@aidsproject.org”

**TAP’s mailing address**

When writing to TAP in Portland, please send your mail to our post office box. It really rushes mail delivery if letters are not addressed to our street address, so write us at:
P.O. Box 5305, Portland, ME 04101

**in the affirmative**

*In The Affirmative* is a monthly newsletter published by The AIDS Project for people living with and affected by HIV/AIDS. Letters, articles, or other submissions should be sent to: *In The Affirmative*, c/o The AIDS Project, P.O. Box 5305, Portland, ME 04101, or call (207) 774-6877. Submissions may be printed anonymously as long as the person submitting the material includes his or her name and phone number for verification.

News, information, and features are up-to-date as possible prior to publication. Any medical information included in this newsletter is submitted for the reader’s information only, to be used as the reader so chooses.